356 related articles for article (PubMed ID: 27989244)
21. Does Quick Sepsis-Related Organ Failure Assessment Suggest the Use of Initial Empirical Carbapenem Therapy in Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Bacteria? :A Multicenter Case-Control Study.
Mitsuboshi S; Tsuruma N; Watanabe K; Takahashi S; Nakashita M; Ito A; Kobayashi K; Tsugita M
Jpn J Infect Dis; 2019 Mar; 72(2):124-126. PubMed ID: 30381688
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
Gudiol C; Royo-Cebrecos C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Tebe C; Carratalà J;
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584145
[TBL] [Abstract][Full Text] [Related]
23. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
[TBL] [Abstract][Full Text] [Related]
24. Is It Time to Rethink the Notion of Carbapenem-Sparing Therapy Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bloodstream Infections? A Critical Review.
Chastain DB; White BP; Cretella DA; Bland CM
Ann Pharmacother; 2018 May; 52(5):484-492. PubMed ID: 29239220
[TBL] [Abstract][Full Text] [Related]
25. Clinical and molecular analysis of extended-spectrum {beta}-lactamase-producing enterobacteria in the community setting.
Arpin C; Dubois V; Maugein J; Jullin J; Dutilh B; Brochet JP; Larribet G; Fischer I; Quentin C
J Clin Microbiol; 2005 Oct; 43(10):5048-54. PubMed ID: 16207960
[TBL] [Abstract][Full Text] [Related]
26. Risk factors associated with preoperative fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in liver transplant recipients.
Bert F; Larroque B; Dondero F; Durand F; Paugam-Burtz C; Belghiti J; Moreau R; Nicolas-Chanoine MH
Transpl Infect Dis; 2014 Feb; 16(1):84-9. PubMed ID: 24330161
[TBL] [Abstract][Full Text] [Related]
27. Key demographic characteristics of patients with bacteriuria due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in a multiethnic community, in North West London.
Gopal Rao G; Batura D; Batura N; Nielsen PB
Infect Dis (Lond); 2015; 47(10):719-24. PubMed ID: 26077035
[TBL] [Abstract][Full Text] [Related]
28. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
[TBL] [Abstract][Full Text] [Related]
29. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.
Palacios-Baena ZR; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina Gil-Bermejo J; Hernández A; Venditti M; Prim N; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Paño-Pardo JR; Torre-Cisneros J; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual Á; Rodríguez-Baño J;
Clin Infect Dis; 2017 Oct; 65(10):1615-1623. PubMed ID: 29020250
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae.
Nakai H; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Yamagishi Y; Mikamo H
J Infect Chemother; 2016 May; 22(5):319-26. PubMed ID: 26968486
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project).
Pierrotti LC; Pérez-Nadales E; Fernández-Ruiz M; Gutiérrez-Gutiérrez B; Tan BH; Carratalà J; Oriol I; Paul M; Cohen-Sinai N; López-Medrano F; San-Juan R; Montejo M; Freire MP; Cordero E; David MD; Merino E; Mehta Steinke S; Grossi PA; Cano Á; Seminari EM; Valerio M; Gunseren F; Rana M; Mularoni A; Martín-Dávila P; van Delden C; Hamiyet Demirkaya M; Koçak Tufan Z; Loeches B; Iyer RN; Soldani F; Eriksson BM; Pilmis B; Rizzi M; Coussement J; Clemente WT; Roilides E; Pascual Á; Martínez-Martínez L; Rodríguez-Baño J; Torre-Cisneros J; Aguado JM;
Transpl Infect Dis; 2021 Jun; 23(3):e13520. PubMed ID: 33222379
[TBL] [Abstract][Full Text] [Related]
32. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
[TBL] [Abstract][Full Text] [Related]
33. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
[TBL] [Abstract][Full Text] [Related]
34. Relationship between digestive tract colonization and subsequent ventilator-associated pneumonia related to ESBL-producing Enterobacteriaceae.
Houard M; Rouzé A; Ledoux G; Six S; Jaillette E; Poissy J; Préau S; Wallet F; Labreuche J; Nseir S; Voisin B
PLoS One; 2018; 13(8):e0201688. PubMed ID: 30089150
[TBL] [Abstract][Full Text] [Related]
35. Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting.
Arpin C; Quentin C; Grobost F; Cambau E; Robert J; Dubois V; Coulange L; André C;
J Antimicrob Chemother; 2009 Jun; 63(6):1205-14. PubMed ID: 19329798
[TBL] [Abstract][Full Text] [Related]
36. Role of Early De-escalation of Antimicrobial Therapy on Risk of Clostridioides difficile Infection Following Enterobacteriaceae Bloodstream Infections.
Seddon MM; Bookstaver PB; Justo JA; Kohn J; Rac H; Haggard E; Mediwala KN; Dash S; Al-Hasan MN
Clin Infect Dis; 2019 Jul; 69(3):414-420. PubMed ID: 30312362
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward.
Meini S; Laureano R; Tascini C; Arena F; Fani L; Frullini A; Passaleva MT; Roberts AT; Mannini D; Sbrana F; Ripoli A; Rossolini GM
Eur J Intern Med; 2018 Feb; 48():50-56. PubMed ID: 29089174
[TBL] [Abstract][Full Text] [Related]
38. Evolution of antibiotic treatments for healthcare-associated infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in France.
Lecuru M; Daniau C; Alfandari S; Dumartin C; Bajolet O; Blanchard H; Simon L; Anne-Berger-Carbonne ; Colomb-Cotinat M
Infect Dis Now; 2022 Oct; 52(7):396-402. PubMed ID: 36041699
[TBL] [Abstract][Full Text] [Related]
39. Detecting risk and predicting patient mortality in patients with extended-spectrum β-lactamase-producing Enterobacteriaceae bloodstream infections.
Trecarichi EM; Cauda R; Tumbarello M
Future Microbiol; 2012 Oct; 7(10):1173-89. PubMed ID: 23030423
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli.
Wu UI; Yang CS; Chen WC; Chen YC; Chang SC
J Microbiol Immunol Infect; 2010 Aug; 43(4):310-6. PubMed ID: 20688291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
